The ongoing clinical trial delivering KRAS G12D siRNA in mesenchymal stromal cell-derived iExosomes to pancreatic cancer patients with KRAS G12D mutations will be beneficial to elucidate the challenges and therapeutic efficacy of delivering KRAS siRNAs with iExosomes (NCT03608631 (M.D. Anderson Cancer Center, 2021b)) Table 1. This evidence concerns the gene KRAS and familial pancreatic carcinoma.